Abstract: A fluid connector assembly. The fluid connector assembly includes a tab portion including a slot; a plug portion slidably connected to the tab portion the plug portion comprising a fluid path and a disc, the disc configured to seat within the slot; a catch feature located on a first end of the tab portion and configured to interact with a reservoir; and a latching feature located on a second end of the tab portion, the latching feature configured to interact and lock onto the reservoir, wherein force applied to the plug portion may overcome a threshold force and unseat the disc from the slot wherein the plug portion moves with respect to the tab portion.

Abstract: This invention provides for methods of treating one or more of endotoxemia, sepsis, colitis, elevated cytokine levels and an inflammatory condition in a subject in need thereof, which comprises administering an effective amount of a composition comprising purified choline acetyl transferase (ChAT) or purified ChAT conjugated to polyethylene glycol (PEGylated ChAT) and a pharmaceutically acceptable carrier to said subject.

Abstract: A blood circuit assembly with a vial holder for a blood pump cassette with a circular receiver and pads to center the vial holder. A blood circuit assembly may include a single, unitary member that defines portions of a pair of blood pumps, control valves, channels to accurately position flexible tubing for an occluder, an air trap support, and/or other portions of the assembly. The occluder door interaction with the unitary member provides added safety checks. A blood circuit assembly engagement device may assist with retaining a blood circuit assembly on the dialysis unit, and/or with removal of the assembly. A dialysate circuit assembly includes a balance pod with a stiffening elements to improve durability.

Abstract: The present invention generally relates to hemodialysis and similar dialysis systems, including a variety of systems and methods that would make hemodialysis more efficient, easier, and/or more affordable. One aspect of the invention is generally directed to new fluid circuits for fluid flow. In one set of embodiments, a hemodialysis system may include a blood flow path and a dialysate flow path, where the dialysate flow path includes one or more of a balancing circuit, a mixing circuit, and/or a directing circuit. Preparation of dialysate by the preparation circuit, in some instances, may be decoupled from patient dialysis. In some cases, the circuits are defined, at least partially, within one or more cassettes, optionally interconnected with conduits, pumps, or the like. In one embodiment, the fluid circuit and/or the various fluid flow paths may be at least partially isolated, spatially and/or thermally, from electrical components of the hemodialysis system.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: The present invention provides methods for modulating antigen-specific antibody responses by administering to a mammal a compound that selectively either activates or inhibits a specific subset of sensory neurons that express TRPV1.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Method and apparatuses for reducing bleeding in a hemophilic patient are described herein. Vagus nerve stimulation augments clotting at the site of injury without precipitating systemic thrombosis, and may be applied to reduce traumatic bleeding in hemophilia A subjects. In particular, vagus nerve stimulation may be applied to reduce traumatic bleeding in hemophilia A subjects that have not received a clotting factor.

Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Provided SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies and fragments thereof, which inhibit the interaction between the spike protein RBM and human ACE2, as well as methods of use employing such antibodies and/or fragments.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Apparatuses and methods for reducing or limiting bleeding in an animal by focused ultrasound (FUS) stimulation of the spleen. The apparatuses and methods may be used treat blood disorders such as hemophilia, or to reduce hemorrhage in surgery or due to traumatic injury. The methods may be non-invasively administered to the patient by transcutaneous application of ultrasound energy.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.